← Human Trials & Peer-Reviewed Studies
The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism.
Plain-language guide to PMID 23604333 (2013): double-blind controlled clinical trial of Therapeutic nicotine (patch, non-peptide) in 52 volunteers.
Key Facts
- PMID
- 23604333
- Journal
- Psychopharmacology
- Year
- 2013
- Study type
- Controlled Clinical Trial
- Authors
- Petrovsky N et al. (9 authors)
- DOI
- 10.1007/s00213-013-3081-1
What This Study Did, in Plain Language
What Was Tested
This controlled clinical trial looks at Therapeutic nicotine (patch, non-peptide).
The researchers tested whether this CHRNA3 polymorphism also modulates the nicotine-induced enhancement of PPI.
Why It Was Studied
Prepulse inhibition (PPI) of the acoustic startle response, a measure of sensorimotor gating, can be enhanced by nicotine.
Who Took Part
According to the abstract, 52 volunteers were involved.
By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.
The researchers assessed the effect of nicotine on PPI, startle reactivity, and habituation in 52 healthy nonsmoking volunteers genotyped for CHRNA3 rs1051730 in a double-blind, placebo-controlled, counterbalanced, within-subjects design.
How the Study Was Run
In design terms this was a double-blind and placebo-controlled study.
Neither the volunteers nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.
Some volunteers received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.
Additionally, cotinine plasma levels were measured.
What Was Measured
Prepulse inhibition (PPI) of the acoustic startle response, a measure of sensorimotor gating, can be enhanced by nicotine.
Topics PubMed links to this paper include Acoustic Stimulation, Administration, Cutaneous, Genetic Variation, Nicotine, Polymorphism, Genetic, Receptors, Nicotinic and Reflex, Startle.
What This Means in Plain Language
The paper is a double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 52 volunteers.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2013 (Psychopharmacology), a journal based in Germany.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.